An additional phase III study evaluating gedatolisib combined with palbociclib and fulvestrant in patients with HR+/HER2− advanced breast cancer that progressed after treatment with a CDK4/6 inhibitor and an aromatase inhibitor is also underway (NCT05501886). This evidence concerns the gene CYP19A1 and breast cancer.